A reasonable idea, suggests Sekar Kathiresan, MD, co-founder and CEO of Verve Therapeutics, is the development of a one-time treatment—a single spelling change in the DNA of a liver gene in an adult ...
David R. Liu, PhD, joined the Harvard University chemistry faculty in 1999 at the tender age of 26 years. When you excel at research through high school, undergraduate, and PhD, postdoctoral ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback